Could a person with diabetes someday trade daily insulin injections for implanted cells that sense glucose and release insulin? That question carries real hope, but it also deserves a straight answer: a cell-based therapy for diabetes must prove that it can work safely and reliably in people before anyone can call it a solution.
Avaí Bio and Austrianova have announced an agreement in principle with an unnamed, internationally acclaimed partner to supply insulin-producing cells for Insulinova, their joint diabetes program. It is an important supply-chain milestone for a preclinical program, but it is not clinical proof, regulatory approval, or an available treatment. [1]
The Cell-Based Therapy for Diabetes Milestone, Explained
Insulinova is a joint venture created by Avaí Bio and Austrianova in late 2025. Its proposed approach combines cells that have been programmed to produce insulin with Austrianova’s Cell-in-a-Box® encapsulation technology. [1]
The goal is simple to describe and difficult to achieve. After implantation, the cells would ideally sense changes in glucose and release insulin in response, trying to imitate a key job normally performed by pancreatic beta cells.
The press release says the new supplier agreement is subject to definitive agreements and customary closing conditions. In plain English, the companies have agreed on terms, but the final documents still needed to be executed when the announcement was made. [1]
That distinction matters. A partnership agreement can put an early program on firmer ground, yet it cannot tell us whether the implanted cells will survive, respond to glucose as intended, avoid an immune attack, or help people reduce insulin use.
Why Cell Supply Is More Than a Back-Office Detail
It is tempting to treat a cell-supply agreement as business news with little relevance to patients. For an experimental cell therapy, that would be like treating the engine as a minor detail in a car: without a dependable engine, the rest of the design does not go anywhere.
A potential therapy needs cells with consistent identity, quality, and performance. The program also needs enough of those cells to support research, manufacturing development, and, if the science earns it, future clinical testing.
This is why the announcement is meaningful even before any patient data exist. It suggests the partners are addressing one of the basic building blocks required to advance their program rather than merely describing an idea.
The cell source also matters because cells must do a highly specialized job. They need to produce insulin, respond appropriately to changing glucose levels, and continue functioning after implantation without causing unacceptable safety problems.
Researchers working with reprogrammed cells face a related question: how do we guide cells into the exact identity needed for a therapeutic task? Our overview of how iPSC regenerative medicine works explains why turning a cell into the right cell type is one of the central challenges in this area of research.
Insulinova’s Proposed Two-Part Strategy
The announcement describes two linked pieces: insulin-producing cells and a protective delivery system. We need both pieces to work, because strong cells without a protective home may not survive long enough to help, while a well-designed capsule cannot compensate for cells that do not perform as required.
| Program component | Proposed role | What still needs to be shown |
|---|---|---|
| Insulin-producing cells | Produce insulin in response to glucose changes | Consistent function, appropriate glucose response, and durability after implantation |
| Cell-in-a-Box® encapsulation | House and protect implanted cells while allowing exchange with the surrounding environment | Long-term cell survival, sufficient nutrient and oxygen transfer, and reliable performance in people |
| Cell-supply collaboration | Provide a dependable source of the cells for the program | Final closing of the agreement and the ability to support development at appropriate quality and scale |
Austrianova states that its encapsulation platform has been studied with other cell-based applications and is meant to protect cells while allowing biologically active compounds to move out. The press release positions this technology as a potential way to support glucose-responsive insulin production, but it does not report Insulinova-specific human data. [1]
That boundary is vital. In regenerative medicine, a platform’s past experience can make a research plan more plausible, yet it cannot substitute for evidence from the exact product, disease, dose, and patient population being discussed.
The Immune System Is Still the Hardest Opponent in the Room
The body’s immune system is not being difficult for the sake of it. It is doing its job, like a security team that treats unfamiliar cells as potential intruders, which is helpful during infection but difficult for a cell implant.
A cell therapy for diabetes must therefore solve more than insulin production. It also needs a durable strategy for preventing rejection or reducing the burden of immune-suppressing medicines while keeping the implanted cells healthy.
Insulinova’s proposed encapsulation system is relevant because a physical barrier could potentially help protect implanted cells. However, whether its design can meet the real-world demands of long-term glucose control remains an unanswered clinical question.
The broader research community is exploring several paths. Some programs use immune-suppressing drugs, some are working on immune-evasive cells, and others are testing devices intended to create a safer home for implanted cells.
This is also why terms such as “allogeneic” matter. An allogeneic therapy uses cells from a donor or other source rather than the patient’s own cells, and our guide to autologous versus allogeneic stem cells unpacks the practical trade-offs behind that choice.
What a More Advanced Program Shows, and What It Does Not
We do have a useful proof-of-concept from a different, more advanced cell-therapy program. In a phase 1–2 study of Vertex’s stem-cell-derived islet therapy zimislecel, all 14 participants who completed at least 12 months of follow-up showed evidence of engraftment and islet function. [2]
Among 12 participants who received the full dose, 10 were insulin-independent at day 365. The study was small and short-term, and every participant received immunosuppressive therapy, so the result should be read as a serious scientific signal, not a universal answer for everyone with type 1 diabetes. [2]
The study also reported significant safety concerns, including neutropenia as the most common serious adverse event and two deaths in the study population. Those findings reinforce a difficult truth: replacing beta-cell function is a major achievement, but safety, immune management, and long-term durability must sit at the center of the conversation. [2]
Zimislecel does not validate Insulinova as a therapy. It does show that restoring insulin production with stem-cell-derived islet cells can move from laboratory theory into human research, which helps explain why early programs such as Insulinova draw attention.
What Patients Should Take From This News Today
For people living with diabetes, it is easy to see a headline about ending injections and feel pulled between hope and exhaustion. We should not punish that hope, but we must put it on solid ground.
Here is the honest read: Avaí Bio and Austrianova have announced a meaningful developmental milestone. They have not announced a clinical trial result, a proven treatment, a Food and Drug Administration approval, or a way for patients to stop taking prescribed insulin.
Anyone using insulin should continue their current plan unless their own qualified healthcare professional changes it. An announcement about a preclinical program is never a reason to alter medication, insulin dosing, glucose monitoring, or diabetes care.
This kind of disciplined optimism is not negativity. It is how we protect ourselves from the hype cycle while leaving room for real advances to earn our attention through data.
Our article on whether stem cell therapy is a cure offers a useful framework for judging similar claims. The tough-love version is this: promising science deserves curiosity, but only evidence deserves confidence.
The Questions That Must Be Answered Next
Before any experimental cell therapy can become a dependable option for patients, researchers need clear answers to several questions. We need to know whether the cells survive, whether they sense glucose accurately, how long they continue working, and whether the body tolerates the implant over time.
We also need rigorous safety data. That includes risks linked to the implant procedure, the device or capsule, the cell product, unwanted immune reactions, and any medicines used to prevent rejection.
Manufacturing questions are equally important. If a therapy works in a small research setting, can it be produced consistently for many people without losing the quality that made it work in the first place?
The science of making specialized cells is central to this work. Our explainer on how stem cells choose their destiny provides a deeper look at why cell identity, maturity, and function deserve as much scrutiny as a promising headline.
A Meaningful Step, Not the Finish Line
The newly announced supplier agreement gives Insulinova a stronger foundation to move its research forward. It puts one important piece of the puzzle in place, but the puzzle is far from complete.
We should watch for confirmation that the definitive agreement has closed, followed by preclinical data, trial registration, peer-reviewed results, and clear safety reporting. Those are the milestones that could change the story from a promising concept into evidence that patients and clinicians can weigh responsibly.
The future of diabetes care may include implanted cells that restore insulin production. Today, Insulinova remains a preclinical program with a newly announced supply agreement, and that is exactly where our expectations should stay until the data tell us more.
References
[1] Avaí Bio and Austrianova’s cell-supply announcement, July 21, 2026.
[2] Reichman TW, et al. Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes. New England Journal of Medicine. 2025;393:858–868.
